<DOC>
	<DOC>NCT00974376</DOC>
	<brief_summary>This is a clinical study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.</brief_summary>
	<brief_title>Gabapentin Treatment of Cannabis Dependence</brief_title>
	<detailed_description>This is a 12-week, double blind, placebo controlled study to evaluate the efficacy of gabapentin in treating outpatients with cannabis dependence. After an initial phone screen, a comprehensive screening visit is scheduled to determine eligibility. Baseline assessments using measurement instruments are conducted on cannabis use, neuropsychological functioning, withdrawal, craving, pain, mood and sleep. Upon enrollment, counseling, medication dispensation and research assessments occur 1 time per week for 3 months and include assessments in withdrawal, craving, pain, mood and sleep. A final, follow-up visit occurs at the end of the 3 months.</detailed_description>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Males or females from 1865 years of age Meets DSM IV criteria for current cannabis dependence Seeking researchbased outpatient treatment for cannabis dependence that involves daily medication Smoked MJ daily at least 25 days per month during the 90 days prior to randomization At least a 2year history of regular MJ use Abstinent from cannabis more than 2 days at the time of randomization Active suicidal ideation Currently meets DSM IV criteria for abuse or dependence on other substances, or has urine drug screen positive for substances, other than cannabis or nicotine Significant medical disorders that will increase potential risk or interfere with study participation, Sexually active female participants with childbearing potential who are pregnant, nursing or refuse to use a reliable method of birth control Meets DSM IV criteria for a major AXIS I disorder other than cannabis and nicotine dependence, Inability to understand and/or comply with the provisions of the protocol and consent form Treatment with an investigational drug during the previous month Sensitivity to study drug as evidenced by adverse drug experiences with gabapentin or its ingredients Ongoing treatment with medications that may affect study outcomes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cannabis Treatment</keyword>
	<keyword>Cannabis Use</keyword>
	<keyword>Cannabis Dependence</keyword>
	<keyword>Executive Functioning</keyword>
	<keyword>Cognitive Deficits</keyword>
</DOC>